Efficacy And SafetyPromising deep and durable responses support Descartes-08's potential in treating myasthenia gravis, offering patients freedom from chronic therapies.
Regulatory ProgressAll important regulatory discussions were completed prior to personnel changes at the FDA, indicating a smooth path forward.
Trial OutcomesPhase 2b results set up Descartes-08 for success in the planned Phase 3 AURORA trial, significantly outperforming placebo.